Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase
Arthur Quan Tran*, Daniel O. Erim, Stephanie A. Sullivan, Ashley L. Cole, Emma L. Barber, Kenneth H. Kim, Paola A. Gehrig, Stephanie B. Wheeler
Dive into the research topics of 'Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase'. Together they form a unique fingerprint.